Latest News for: in vivo
Edit
Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic
Business Wire 24 Dec 2025
Edit
Precision Meets Affordability, Ace Therapeutics Unveils In Vivo Efficacy Testing Services for IBD Drug Candidates
GetNews 19 Dec 2025
Edit
Vyriad Unveils Lead In Vivo CAR T Candidate VV169 and Data Supporting Future Clinical Development ...
Business Wire 16 Dec 2025
Edit
Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering
Pharmiweb 16 Dec 2025
Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering ... · Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM .
Edit
Vyriad Unveils Lead In Vivo CAR T Candidate VV169 and Data Supporting Future Clinical Development During ASH 2025
Pharmiweb 16 Dec 2025
Edit
Caledonian Record
15 Dec 2025
Manifold Bio Expands Leadership Team to Drive its AI + In Vivo Targeted Biologics Platform
Edit
Brattleboro Reformer
10 Dec 2025
CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR ...
Edit
The Eagle-Tribune
10 Dec 2025
Ensoma Announces Clearance of U.K. Clinical Trial Authorization Application for EN-374, First In Vivo HSC-Directed ...
Edit
Profluent Bio Announces Strategic Collaboration with Ensoma to Develop AI-Designed Base Editors for In Vivo ...
Business Wire 09 Dec 2025
Edit
Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA ...
Business Wire 09 Dec 2025
... presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando, Florida.
Edit
“F.A.T. LABORATORIES” – IN VITRO, IN VIVO, IN SILICO APPROACHES FOR THE DEVELOPMENT OF DRUGS, GENERICS, AND SUPERGENERICS (National and Kapodistrian University of Athens)
Public Technologies 09 Dec 2025
Laboratories aims to play a significant role in accelerating and reducing the cost of drug and generic development ... development in the pharmaceutical sector. We wish every success in this new venture!.
Edit
Qihan Biotech Presents New Clinical Data on Allogeneic CAR-T Cell Therapies and Preclinical Data on In Vivo CAR-T at the American Society of Hematology (ASH) Annual Meeting
Pharmiweb 09 Dec 2025
– Additional preclinical findings presented at ASH provide the scientific foundation for Qihan’s in vivo CAR-T platform – ... Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics.
Edit
CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy
PR Newswire 09 Dec 2025
Edit
Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting
Pharmiweb 09 Dec 2025
The company’s elegant, cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modification to improve in vivo gene transfer efficiency and tropism molecules to facilitate tissue-specific delivery.
Edit
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic ...
Nasdaq Globe Newswire 08 Dec 2025
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology� ... .
- 1
- 2
- Next page »